Ashvattha Therapeutics Announces First Patient Enrolled in Expanded Phase 1/2 Study of Imaging Agent 18F-OP-801 in Additional Neurological Indications

The study will evaluate the safety, tolerability, and ability of 18F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease Preliminary data expected in 1H 2024 REDWOOD CITY, Calif., February 22, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new … Read more

Ashvattha Therapeutics to Present at UBS Global Healthcare Conference 2022

REDWOOD CITY, Calif., May 5, 2022 – Ashvattha Therapeutics, (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced that Jeffrey Cleland, Ph.D., Chairman, CEO & President of Ashvattha, will provide a corporate overview followed by a moderated Q&A at the UBS Global Healthcare Conference 2022 taking place in New York, NY, May … Read more

Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous anti-VEGF wet AMD and DME Candidate at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Data showed single subcutaneous doses of D-4517.2 were safe and well tolerated in healthy subjects D-4517.2 exposure in healthy subjects translates to efficacious doses in choroidal neovascularization (CNV) in mouse model Initiation of Phase 2 study evaluating D-4517.2 in patients with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME) expected in mid-2022 … Read more